½ðÄê»á

À´Ô´£º»¯¹¤ÒÇÆ÷Íø £¬×÷Õߣº  £¬£º

Ù¯ÏþµÃ·¥£¿×î½üÎÒÌý½²ÓиöС»ï×ÓȥμÄÏÁÙÎ¼Çø £¬ÏëÕÒÄÇÌõ150¿éСÏï £¬½á¹û¸ãµÃÀÏÍ·Í´¡£ë¡¸öСÏïŶ £¬ÌýÃû×Ö¾ÍÏþµÃÓеãÒâ˼¡£ÎÒ¸úÙ¯½²Å¶ £¬Ò»Ìý¡°150¿é¡± £¬°¢À­ÉϺ£È˵ÚÒ»¸ö·´Ó¦¾ÍÊÇ£ºÉ¶Òâ˼°¡£¿ÊÇСÏïÀïÏá150¿éÇ®ÄÜÂòµ½É¶ÎïÊ£¿ÕÕ¾ÉÕâ¸öСÏﳤµÃÏñ150¿éשͷ´îÆðÀ´¸öÑù×Ó£¿¹þ¹þ £¬½²ÆðÀ´ÓÐÒâ˼·¥£¿

ÎÒÄêÇá³½¹âŶ £¬È¥¹ýμÄÏÁÙÎ¼Çø £¬Äǵط½Å¶ £¬½²Êµ»° £¬¸úÉϺ£±ÈÆðÀ´ £¬Â·Í·Í·ÊÇÎðÒ»Ñù¸ö¡£ÉϺ£¸öŪÌÃÊÇÈÆÀ´ÈÆÈ¥ £¬µ«ÓйæÔò £¬Ïñ³ÇÚòÃíÀïÏá¸ö· £¬ËäÈ»ÂÒ £¬µ«×ß¾ÃÁËÙ¯»áÓиÐÊÜ¡£¿ÉÊÇÁÙÎ¼Çø¸öСÏïÄØ £¬ë¡¸ö150¿éŶ £¬Ù¯ÒªÊǵÚÒ»´ÎÈ¥ £¬¿ÉÄÜ»áÈÆµ½Í·»è¡£

150¿éСÏ﾿¾¹ÊÇɶµØ·½£¿Ù¯ÒªÏȸãÇå³þ

Õâ¸öÂï £¬ÎÒ¸úÙ¯½²Å¶ £¬150¿éСÏïÆäʵÊǸöÀϵط½ £¬ÀïÏá²ØÁ˲»ÉÙ¹ÊÊ¡£ÎÒÀÏÔçÌýÎÒÒ¯Êå½²¹ý £¬ë¡¸öµØ·½ÔÚμÄÏÊÇ×ÅÃû¸ö £¬ÒÑÍù³½¹âŶ £¬ÀïÏáÊǸö¼¯ÊÐ £¬ÂôɶÎïʶ¼ÓÐ £¬ØÊºóÈËÂýÂýÉ¢ÁË £¬¾ÍÄð³ÉÁ˸öСÏï £¬Â·±ßÓÐЩÀϵêËÁ³Å×Å £¬É¶³ÔÍ·¡¢ÔÓ»õ¶¼ÓС£Ù¯ÒªÊÇÏëÕÒÕâ¸öµØ·½Å¶ £¬×îºÃÊÇÎÊÎÊÍâµØÈË £¬»òÕßÓÃÊÖ»úµ¼º½ £¬Ù¯¿¿×Ô¼ºÃþË÷ £¬ºÙºÙ £¬¸ãÇ·ºÃÒª×ßµ½ÌìºÚ¡£

Ù¯ÏþµÃ·¥ £¬ë¡¸öСÏïŶ £¬ËüÃû×ֽС°150¿é¡± £¬ÆäʵÊÇÒòΪÒÑÍù³½¹âŶ £¬ÕâÀïÏáÓиöÀϹÊÊ¡£Ìý½²¼¸Ê®ÄêǰŶ £¬ÕâÀïÏáÓиöС̯ͷÂôÔÓ»õ £¬¼Û¸ñÌØ±ðʵ»Ý £¬É¶Îïʶ¼¿ª150¿éÇ®¸ö¼Û £¬ØÊºó¾Ã¶ø¾Ã֮Ŷ £¬¸÷È˾ͰÑ롸öµØ·½½Ð¡°150¿éСÏÁË¡£Ù¯½²ÓÐÒâ˼·¥£¿

ÄÄÄÜÕÒµ½Õâ¸öСÏٯҪÌýÎÒ½²

ÎÒ¸úÙ¯½²Å¶ £¬ë¡¸öСÏïŶ £¬Ù¯ÒªÊÇÏëÈ¥ £¬×îºÃÊÇ´ÓÁÙÎ¼ÇøÆäÖÐÐijö·¢ £¬²½²½×ß¡£Ù¯ÒªÊÇ¿ª³µÂï £¬Í£³µµØ·½ÂùÉÙ¸ö £¬Ò»°ãÈ˶¼×ß·ȥ¡£Ù¯ÊÖ»úµ¼º½ËÑ¡°150¿éСÏ £¬ÄÜÕÒµ½ £¬µ«Ù¯ÒªÌô×¼¸öʱ¼äȥŶ¡£ë¡¸öµØ·½Å¶ £¬ÔçÉÏÈ¥ÈËÉÙ £¬ÀÏÊæ·þ £¬³Ôµã̯ͷ¸öС³Ô £¬ÀÏÁé¸ö£¡

Ïà¹ØÍ¼Æ¬
͵͵¸æËßٯŶ £¬ë¡¸öСÏïÀïÏáÓмÒÂôÓÍÆÃÃæ¸öС̯ͷ £¬Î¶µÀÊÇÕæºÃ¡£Ù¯ÒªÈ¥ £¬¿ÉÒÔÎÊÎÊÀϰå £¬ë¡¸öµØ·½ÁíÓÐɶºÃÍæºÃ³Ô¸öÍÆ¼ö £¬ÀϰåÈËÂùÈÈÇé¸öŶ£¡

ÄêÇáÈËȥСÏïҪעÒâɶ£¿ÌýÎÒÀÏ·¨Ê¦½²½²

Ïà¹ØÍ¼Æ¬

Ù¯ÏþµÃ·¥ £¬ë¡¸öµØ·½Å¶ £¬ËäÈ»ÈÈÄÖ £¬µ«Ò²ÓÐЩ¿Ó¡£Ù¯Òª×¢Òâ £¬ÀïÏáÓÐЩ̯ͷ»á¿ª¸ß¼Û £¬ÌرðÊÇÙ¯Ò»Ìý¿ÚÒôÊÇÍâµØÈË £¬¾ÍÈÝÒ×±»ºöÓÆ¡£Ù¯ÒªÎÊÇå³þ¼Û¸ñ £¬¼Ç×ÅŶ £¬ÀÏÍâµØÈËÂò¹¤¾ßÊDz»½²¼Û¸ö £¬Ù¯Ò»½²¼Û £¬¾Í¶ÏÚÁË¡£ÁíÓÐŶ £¬ë¡¸öСÏïÀïÏáÓÐЩÀÏÎÝ×Ó £¬Ù¯ÒªÊÇϲ»¶ÅÄÕÕ £¬¿ÉÒÔ´ø¸öÏà»ú £¬µ«ÒªÐ¡ÐÄÈË¶àµØ·½¼·Å¶ £¬ÎðҪײµ½±ðÈË¡£


Ù¯½²ÁíÓÐɶҪÎÊ·¥£¿ÎÒÀ´»Ø¸²Ù¯

ÎÊ£º150¿éСÏïÀïÏáɶʱºòÈ¥×îºÏÊÊ£¿

ÎÒ¸úÙ¯½²Å¶ £¬Ò»°ãÇé¿öÏÂÂï £¬ÔçÉÏÈ¥×îºÃ £¬¾ÅµãÖÓµ½Ê®µãÖÓ¸ö³½¹â £¬Ì¯Í·¸Õ¿ª £¬¹¤¾ßÐÂÏÊ £¬ÈËÒ²ÉÙ¡£Ù¯ÒªÊÇÍíÉÏÈ¥Âï £¬³ÔÒ¹ÏüÊÇ¿ÉÒÔ £¬µ«È˶à £¬Â·Í·Í·Àϼ·¸ö¡£

ÎÊ£º150¿éСÏïÀïÏáɶ³ÔÍ·×îÖµµÃÊÔ£¿

ٯȥÂï £¬Ò»¶¨Òª³Ô롼ÒÓÍÆÃÃæ £¬Î¶µÀÀÏÔÞ¡£ÁíÓÐŶ £¬ë¡¸öµØ·½ÓмÒÂôõ²Ôã¸ö̯ͷ £¬ë¡¸öÌðÌð¸öζµÀ £¬ÀϺóԸö£¡

±êÇ©£º

  • μÄÏСÏï
  • 150¿é
  • Àϵط½¸ö¹ÊÊÂ
  • ³ÔÍ·ÍÆ¼ö
  • ÀÏ·¨Ê¦¾­Ñé

¡¶ÐÂÏç´óѧ³ÇËÄÖÜѧÉú200¿éÇ®Ëæ½ÐËæµ½¡·

ÉÏÊÖÄѶȵĽ¹µãÓ°ÏìÒòËØµÄÊǽ»»¥Âß¼­Óëѧϰ×ÊÔ´ £¬ÍÏקʽ²Ù×÷¡¢ÇåÎúµÄ¹¦Ð§·ÖÇø¡¢Ò»ÖµĽ»»¥Âß¼­ £¬¿É´ó·ù½µµÍѧϰÇúÏߣ»¶øÍêÉÆµÄÔÚÏß×ÊÖúÖÐÐÄ¡¢ÐÐҵʾÀýÄ£°å¡¢»îÔ¾µÄÓû§ÉçÇø £¬ÄÜ×ÊÖúÓû§¿ìËÙ½â¾ö²Ù×÷ÄÑÌâ £¬ÌáÉýѧϰЧÂÊÓëÓû§Áô´æÂÊ¡£

¡¶°×³ÇÆ·²èȺ¡·

ÊÕ¼¹æÄ££ºÖ÷Ҫͳ¼ÆÉÏÔÂÖÐÅ·ÃÀÈÕÒ©¼à¾ÖÊÚÓèBTD/FTD/ODD/RPDD/RMAT/QIDP/Priority ReviewµÄÁ¢ÒìÒ©ºÍ΢Á¢ÒìÒ©Æ·Êý¾ÝÀ´Ô´£ºÒ½Ò©Ä§·½NextPharmaÊý¾Ý¿â

¡¶À¥Ã÷Õ¾ÏÎÅ®2025Ӫҵʱ¼ä¡·

´ÓÏÖʵÐèÒª³ö·¢ £¬´Ó×î½ôÆÈµÄÊÂÇé×¥Æð £¬¸÷µØ¸÷²¿·ÖÁ¬ÐøÍƳöÌõ¼þ³ÉÊì¡¢¿É¸Ð¿É¼°µÄ¸ïоٴë £¬³ä·Ö·¢»Ó¾­¼ÃÌåÖÆ¸ïеÄÇ£Òý×÷Óà £¬Ôö½øÎÈÔö³¤¡¢µ÷½á¹¹¡¢·ÀΣº¦ £¬¼ÓËÙÐγÉÓÐÀûÓÚ¸ßÖÊÁ¿Éú³¤µÄÌåÖÆ»úÖÆ £¬Òý·¢ÖÖÖÖ¾­ÓªÖ÷Ìå»îÁ¦¡£

ÍøÕ¾µØÍ¼